Direction
Buy
Sell
Types
LMT Order
Price
QTY
Amount
--
09877 JENSCARE-B
40.850-1.350-3.20%
Closed
01/27 16:08 CCT
High
41.400
Open
40.000
Turnover
1.74M
Low
38.200
Pre Close
42.200
Volume
43.60K
Price Forecast
News
Comment
We're Not Very Worried About Jenscare Scientific's (HKG:9877) Cash Burn Rate
There's no doubt that money can be made by owning shares of unprofitable businesses. For example, although Amazon.com made losses for many years after listing, if you had bought and held the shares
Jenscare Scientific's Hong Kong IPO Stabilization Ends With No Overallotment
Jenscare Scientific's Hong Kong IPO Stabilization Ends With No Overallotment
02:37 AM EDT, 10/31/2022 (MT Newswires) -- Jenscare Scientific (HKG:9877) said no overallotment option was exercised in its Hong Kong listing as the stabilization period of its initial public offering
Two PICC companies actively embracing investment in large health industries have been successfully listed on the Hong Kong Stock Exchange.
It is reported that two companies invested in life insurance of PICC, Baosaitu and Jianshi Technology, were successfully listed on the Stock Exchange of Hong Kong a few days ago. Recently, there has been good news from the PICC Health Pension Industry Investment Fund (PICC Health Fund for short), which invests in two enterprises, Beossett and Jianshi Technology, which have been successfully listed on the Hong Kong Stock Exchange one after another. While improving the company's investment income, it fully demonstrates the company's contribution to responding to national policies, implementing the group's six strategic services, empowering enterprises, and promoting a healthy China and scientific and technological self-reliance. October 10, 2022, PICC Health Fund invested by Life Insurance
IPO Trends of Hong Kong stocks: 2350.HK listed today
2350 Gelonghui Sept. 26 (02350.HK) $listed today, $06678.HK (06678.HK) $, $Emmy Vaccine (06660.HK) $, $03931.HK (03931.HK) $, $GC CONSTRUCTION (01489.HK) $and $Jianshi Technology-B (09877.HK) $are in the application period.
Jenscare Scientific Anticipates Up to $30 Million in Hong Kong IPO
11:06 PM EDT, 09/22/2022 (MT Newswires) -- $JENSCARE-B(09877.HK)$ is targeting to raise up to HK$232.6 million ($29.6 million) from its initial public offering in Hong Kong.The high-tech medical equip
No More
Company Overview
More
Ningbo Jianshi Technology Co., Ltd. is a medical device company based in China, dedicated to developing interventional products for the treatment of structural heart disease. The company was established in November 2011 in China. Since then, we have developed a range of treatment solutions for different types of structural heart diseases, including tricuspid valve disease, aortic valve disease, mitral valve disease, and heart failure. Our core product, LUX-Valve, has the potential to treat severe tricuspid valve reflux, and according to Frost & Sullivan's data, since LUX-Valve is the world's first product under development to complete the enrollment of test subjects in confirmatory clinical trials, it is expected to be one of the first transcatheter tricuspid valve replacement products approved for commercialization in the world. Furthermore, according to Frost & Sullivan's data, LUX-Valve was recognized as a “breakthrough medical device” under the Breakthrough Medical Device Program by the US Food and Drug Administration in November 2021, making it the first domestic self-developed medical device in the field of valvular heart disease treatment to receive this certification. Our other core product, Ken-Valve, is designed to treat severe aortic valve reflux (or aortic stenosis combined with aortic stenosis) and is expected to meet the needs of more patients, far greater than the transcatheter aortic valve replacement system for which only treatment of aortic stenosis is indicated. We are also developing eight other products with advanced technology, including (i) JenSclip, an innovative transcatheter mitral valve repair clamping system with many unique designs that make it stand out from other transcatheter mitral valve repair systems on the market; (ii) MitraPatch, an innovative transcatheter mitral valve repair product that uses valve repair technology to repair the mitral valve; and a number of advanced products under development for different types of valvular heart disease and heart failure.
CEO： Shiwen Lv
Market： Hong Kong motherboard
Listing Date： 10/10/2022
Paper Trade
More
Hot List
TradeSearchNews
SymbolLatest price%Chg
Loading...
Watchlist
No Stock Yet